Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- Shirley Ryan AbilityLab
- Study ID
- NCT07132775
- Status
- Recruiting
Conditions
- Fibromyalgia
- Multiple Sclerosis
- Neurologic Disorder
- Neuromuscular Disorders
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Active full-body stimulation — DEVICEParticipants will receive active stimulation through a full-body suit with embedded electrodes that deliver a low-grade electrical stimulation to muscle groups.
- Sham full-body stimulation — OTHERParticipants will receive sham stimulation through a full-body suit with embedded electrodes that deliver a low-grade electrical stimulation to muscle groups.
Study Details
The purpose of this study is to to explore the safety and efficacy of the EXOPULSE Mollii suit, a full-body electrostimulation suit, for individuals with neurological or neuromuscular conditions that cause spasticity, hyperreflexia, and/or pain.
Key Dates
- Start date
- Jul 23, 2025
- Status verified
- Sep 2025
- Primary completion
- Jul 31, 2027
- Completion
- Jul 31, 2027
Study Design
- Enrollment
- 15 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: InterventionParticipants will wear the full-body electrostimulation garment for 60 minutes at a time, every other day, with the stimulation parameters actively running.
- Sham Comparator: ShamParticipants will wear the full-body electrostimulation garment for 60 minutes at a time, every other day, with the stimulation parameters not actively running.
Primary Outcome Measure
Berg Balance Scale [ Time Frame: Baseline 1 (prior to Arm 1)- initial visit, Endpoint 1 (after 2 weeks of Arm 1)- at approx 2 weeks, Baseline 2 (after 2 week washout and before Arm 2)- at approx 4 weeks, Endpoint 2 (after 2 weeks of Arm 2)- at approx 6 weeks ]
Central Contacts
- Arun Jayaraman, PhD312-238-6875
- Sara Prokup, DPT312-238-1355
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Shirley Ryan AbilityLab | Chicago | Illinois | 60611 | Sara Prokup 312-238-1355 |
Find similar trials in Chicago, IL
By condition
By specialty
By research site
Related Studies
- Quality Improvement and Practice Based Research in Neurology Using the EMRPHASE4 · Enrolling By Invitation · Endeavor Health · Evanston, Illinois
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Exercise Training for Managing Major Depressive Disorder in Multiple SclerosisRecruiting · University of Illinois at Chicago · Chicago, Illinois
- An Individualized-health eLibrary App for People With Multiple SclerosisRecruiting · University of Illinois at Urbana-Champaign · Champaign, Illinois